What's in Chiesi Farmaceutici S.p.A.'s pipeline?

Chiesi Farmaceutici S.p.A. has 85 drugs in our index: 12 marketed, 0 filed, 35 in Phase 3, 25 in Phase 2, 13 in Phase 1.

Which companies overlap with Chiesi Farmaceutici S.p.A.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, AstraZeneca, Sanofi, SkyePharma AG, Teva Branded Pharmaceutical Products R&D, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chiesi-farmaceutici-s-p-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Chiesi Farmaceutici S.p.A. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chiesi Farmaceutici S.p.A. pipeline: 12 marketed, 0 filed, 35 Phase 3, 25 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 35 Phase 3 25 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Elfabrio	PEGUNIGALSIDASE ALFA	marketed	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]		Metabolic	2023-01-01
Glycopyrrolate + Formoterol	Glycopyrrolate + Formoterol	marketed	Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination	M3 muscarinic receptor; beta-2 adrenergic receptor	Respiratory / Pulmonology
Beclometasone/Formoterol	Beclometasone/Formoterol	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
Formoterol Inhalation Solution	Formoterol Inhalation Solution	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor	Respiratory
CHF1535	CHF1535	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor	Respiratory/Pulmonology
Foster BDP/Formoterol	Foster BDP/Formoterol	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol)	Respiratory
Atimos®	Atimos®	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic receptor	Respiratory / Pulmonology
elapegademase-lvlr	elapegademase-lvlr	marketed
umeclidinium bromide and vilanterol trifenatate	umeclidinium bromide and vilanterol trifenatate	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor and beta-2 adrenergic receptor	Respiratory / Pulmonology
Foster	Foster	marketed			Other
CHF5993	CHF5993	marketed			Other
Poractant alfa (Curosurf®)	Poractant alfa (Curosurf®)	marketed	Pulmonary surfactant replacement therapy		Respiratory/Neonatology

Therapeutic area mix

Respiratory/Pulmonology · 23
Respiratory · 21
Respiratory / Pulmonology · 9
Other · 2
Metabolic · 1
Cardiovascular · 1
Respiratory/Neonatology · 1
Dermatology / Wound Care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 8 shared drug classes
AstraZeneca · 8 shared drug classes
Sanofi · 6 shared drug classes
SkyePharma AG · 5 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 5 shared drug classes
Pearl Therapeutics, Inc. · 3 shared drug classes
Milton S. Hershey Medical Center · 3 shared drug classes
Research in Real-Life Ltd · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Chiesi Farmaceutici S.p.A.:

Cite this brief

Drug Landscape (2026). Chiesi Farmaceutici S.p.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chiesi-farmaceutici-s-p-a. Accessed 2026-05-17.